International collaboration among Canadian, U.S. and Australian regulators leads to new options for the treatment of cancer

On September 20, 2019, Health Canada authorized a new treatment for women who haveadvanced endometrial cancer through the combined use of Lenvima (lenvatinib) and Keytruda (pembrolizumab).